Abstract
BACKGROUND: Platelet function may be abnormal in patients with atrial fibrillation (AF) and could be related to abnormal thrombogenesis. The aim of this cross-sectional study was to investigate new aspects of platelet biology in AF, predominantly focusing on platelet activation and the effects of concomitant antiplatelet and anticoagulant therapy. PATIENTS AND METHODS: The study group of 238 patients were (i). 93 patients on no antithrombotic therapy, (ii). 60 patients taking 75-325 mg aspirin/day, and (iii). 85 patients on dose-adjusted warfarin (International Normalised Ratio [INR] range 2.0-3.0). Results were compared with those from 50 age- and sex-matched normal subjects. Platelet markers (plasma beta-thromboglobulin, soluble glycoprotein V [both ELISA]), coagulation markers (fibrin D-dimer [ELISA] and fibrinogen [Clauss]), and platelet aggregation in response to standard platelet agonists were studied. RESULTS: beta-thromboglobulin (P=0.01), soluble glycoprotein V (P
| Original language | English |
|---|---|
| Pages (from-to) | 1788-1795 |
| Number of pages | 8 |
| Journal | European Heart Journal |
| Volume | 23 |
| Issue number | 22 |
| DOIs | |
| Publication status | Published - 15 Nov 2002 |
Keywords
- atrial fibrillation
- platelets
- platelet aggregation
- fibrin D-dimer
- soluble glycoprotein V
- betathromboglobulin